|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial显示文摘 | Kris V Kowdley Eric Lawitz Israel Crespo Tarek Hassanein Mitchell N Davis Michael DeMicco David E Bernstein Nezam Afdhal John M Vierling Stuart C Gordon Jane K Anderson Robert H Hyland Hadas Dvory-Sobol Di An Robert G Hindes Efsevia Albanis William T Symo | 2013 | The Lancet2013，，9883： | 3 |
| 2 | Combination immunotherapy with Survivin and luteinizing hormone-releasing hormone fusion protein in murine breast cancer model显示文摘AIM To investigate the therapeutic potential of two recombinant proteins, Survivin and luteinizing hormone-releasing hormone (LHRH) fusion protein [LHRH(6 leu)-LTB] for immunotherapy of breast cancer.METHODS Murine 4 T-1 breast cancer model was used to evaluate the efficacy of recombinant proteins in vivo. Twenty four Balb/c mice were divided into 4 groups of 6 mice each. Recombinant Survivin and LHRH fusion protein, alone or in combination, were administered along with immunomodulator Mycobacterium indicus pranii (MIP) in Balb/c mice. Unimmunized or control group mice were administered with phosphate buffer saline. Each group was then challenged with syngeneic 4 T-1 cells to induce the growth of breast tumor. Tumor growth was monitored to evaluate the efficacy of immune-response in preventing the growth of cancer cells.RESULTS Preventive immunization with 20 μg recombinant Survivin and MIP was effective in suppressing growth of 4 T-1 mouse model of breast cancer (P = 0.04) but 50 μg dose was ineffective in suppressing tumor growth. However, combination of Survivin and LHRH fusion protein was more effective in suppressing tumor growth (P = 0.02) as well as metastasis in vivo in comparison to LHRH fusion protein as vaccine antigen alone.CONCLUSION Recombinant Survivin and MIP suppress tumor growth significantly. Combining LHRH fusion protein with Survivin and MIP enhances tumor suppressive effects marginally which provides evidence for recombinant Survivin and LHRH fusion protein as candidates for translating the combination cancer immunotherapy approaches. | Himani Garg Rohit Singh Hada Jagdish C Gupta G P Talwar Shweta Dubey | 2018 | World Journal of Clinical Oncology2018，9，8： | 2 |
| 3 | Host-specificity of Staphylococcus aureus causing intramammary infections in dairy animals assessed by genotyping and virulence genes显示文摘 | BAR-GAL G K BLUM S E HADAS L | 2015 | Vet Microbiol2015，176，12： | 1 |
| 4 | Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial显示文摘 | Kris V Kowdley Eric Lawitz Israel Crespo Tarek Hassanein Mitchell N Davis Michael DeMicco David E Bernstein Nezam Afdhal John M Vierling Stuart C Gordon Jane K Anderson Robert H Hyland Hadas Dvory-Sobol Di An Robert G Hindes Efsevia Albanis William T Symo | 2013 | The Lancet2013，，9883： | 1 |
| 5 | Ancient agricultural irrigation systems in the oasis of Ein Gedi, Dead Sea, Israel显示文摘 | Hadas G | 2012 | Journal of Arid Environ- ments2012，86，： | 1 |
| 6 | Cost-benefit analysis ofgreen buildings:an israeli office buildings case study显示文摘 | HADAS G ISAAC A M MOSHE S ed | 2014 | Energyand Buildings2014，76，6： | 1 |
| 7 | 查看详情显示文摘 | Frisch M J Trucks G W Schlegel H B Scuseria G E Robb M A Cheeseman J R Montgomery J A Jr Vreven T Kudin K N Burant J C Millam J M Iyengar S S Tomasi J Barone V Mennucci B Cossi M Scalmani G Rega N Petersson G A Nakatsuji H Hada M Ehara M Toyota K Fukuda R | | 0，，： | 1 |
| 8 | UV disinfection of indigenous aerobic spores: implications for UV reactor validation in unfiltered water 显示文摘 | Hadas Mamane-Gravetz Karl G Linden | 2004 | Water Research2004，38，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员